Exclusion of Liver Disease and Underutilization of Liver-Specific Endpoints in Heart Failure Trials

IF 10.3 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC. Heart failure Pub Date : 2025-06-03 DOI:10.1016/j.jchf.2025.03.036

Muhammad Shahzeb Khan MD, MSc , Ahmed Mustafa Rashid MBBS , Harriette G.C. Van Spall MD, MPH , Nicolas Girerd MD, PhD , Nicholas W.S. Chew MBBS , Michael L. Volk MD , Javed Butler MD, MPH, MBA , Arun J. Sanyal MD , Faiez Zannad MD, PhD

引用次数: 0

查看原文本刊更多论文

心力衰竭试验中肝脏疾病的排除和肝脏特异性终点的未充分利用

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JACC. Heart failure CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

21.20

自引率

2.30%

发文量

164

期刊介绍： JACC: Heart Failure publishes crucial findings on the pathophysiology, diagnosis, treatment, and care of heart failure patients. The goal is to enhance understanding through timely scientific communication on disease, clinical trials, outcomes, and therapeutic advances. The Journal fosters interdisciplinary connections with neuroscience, pulmonary medicine, nephrology, electrophysiology, and surgery related to heart failure. It also covers articles on pharmacogenetics, biomarkers, and metabolomics.